

SEQUENCE LISTING

SELECTIVELY INHIBIT HEPATITIS C VIRUS REPLICATION

. .. -- **

<110> Katze, Michael G. Gale Jr., Michael J. <120> NOVEL SCREENING METHODS TO IDENTIFY AGENTS THAT

<130> 7960-060

<140> 09/035,619

<141> 1998-03-05

<150> 60/038,596

<151> 1997-03-05

<160> 25

<170> PatentIn Ver. 2.0

<210> 1

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 1

ggaattcgag ctcgcccg

<210> 2

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 2

gctctagaag cacacgacat cttc

<210> 3

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

RECEIVED

TECH CENTER 1600/2900

18

24

<223>	Description of Artificial Sequence: primer	
<400>	3	
ccacto	gagc ggacagttgg ctgg	24
-2105	4	
<210><211>		
<211>		
	Artificial Sequence	
(213)	niciliate ocquence	
<220>		
<223>	Description of Artificial Sequence: primer	
<400>	4	
ccgct	gagt ggtgattctg gtctc	25
<210>	5	
<211>	20	
<212>	DNA	
<213>	Artificial Sequence	
<220>	Description of Artificial Company, rejuse	
<223>	Description of Artificial Sequence: primer	
<400>	5	
	gacgc agcagagat	20
3 33 .		
<210>	6	
<211>	20	
<212>	DNA	
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence: primer	
<400>	<i>c</i>	
	tcacc atcactcagc	20
cagec	couco acoucougo	20
<210>	7	
<211>	30	
<212>	DNA	
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence: primer	
	7	
<400>	/ catgg gctccggctc gtggctaaag	30
		J 0

```
<210> 8
<211> 32
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer
<400> 8
                                                                    32
atcggatcct taggacattg agcagcagac ga
<210> 9
<211> 26
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer
<400> 9
                                                                    26
gtgactggtg aggcctcaac caagtc
<210> 10
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer
<400> 10
                                                                     27
taagcttatg ggctccggct cgtggct
<210> 11
<211> 24
<212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: primer
 <400> 11
                                                                     24
 catatgggct ccggctcgtg gcta
 <210> 12
 <211> 27
 <212> DNA
```

<213>	Artificial Sequence	
<220>	•	
<223>	Description of Artificial Sequence: primer	
<400>	12	
gaatto	cctt ccttgaaggc aacatgc	27
<210>	13	. •
<211>	30	
<212>	DNA ·s	
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence: primer	
<400>	1.3	
ccttc	catgg cccacattac agcagagacg	30
<210>	14	
<211>	27	
<212>	DNA	
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence: primer	
<400>	14	
caago	ttgga tccttaggac attgagc	27
0.1.0		
<210>		
<211>		
	Artificial Sequence	
\Z132	ALCIZIOIGI GOGGOOG	
<220>	>	
<223	> Description of Artificial Sequence: primer	
<400:	> 15	
gtcga	accgca gacaactggc tagctga	27
<210:	> 16	
<211:		
	> DNA	
	> Artificial Sequence	
<220		
<223	> Description of Artificial Sequence: primer	

<400> 16	
atcggatcct tataccacct tattctctga	30
<210> 17	
<211> 30	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: primer	
<400> 17	
atcggatcct tataccacct tattctctga	30
<210> 18	
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: primer	
<400> 18	
gactccccag atgttgacct catc	24
<210> 19	
<211> 45	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: primer	
<400> 19	
ttgtctgcgc tttccttgaa ggcagcatgc actggccgtc acgac	45
<210> 20	
<211> 40	
<212> PRT	
<213> Hepatitis C virus	
<400> 20	
Pro Ser Leu Lys Ala Thr Cys Thr Thr His His Asp Ser Pro Asp Ala	
1 5 10 15	
Asp Leu Ile Glu Ala Asn Leu Leu Trp Arg Gln Glu Met Gly Gly Asn	
20 25 30	

Ile Thr Arg Val Glu Ser Glu Asn
35 40

<210> 21

<211> 40

<212> PRT

<213> Hepatitis C virus

<400> 21

Pro Ser Leu Lys Ala Thr Cys Thr Ala Asn His Asp Ser Pro Asp Ala 1 5 10 . 15

Glu Leu Ile Glu Ala Asn Leu Leu Trp Arg Gln Glu Met Gly Gly Asn
20 25 30

Ile Thr Arg Val Glu Ser Glu Asn
35 40

<210> 22

<211> 40

<212> PRT

<213> Hepatitis C virus

<400> 22

Pro Ser Leu Lys Ala Thr Cys Thr Thr Arg His Asp Ser Pro Asp Ala 1 10 15

Asp Leu Ile Glu Ala Asn Leu Leu Trp Arg Gln Glu Met Gly Gly Asn 20 25 30

Ile Thr Arg Val Glu Ser Glu Asn
35 40

<210> 23

<211> 40

<212> PRT

<213> Hepatitis C virus

<400> 23

Pro Ser Leu Lys Ala Thr Cys Thr Thr Arg His Asp Ser Pro Asp Val

Asp Leu Ile Glu Ala Asn Leu Leu Trp Arg Gln Glu Met Gly Gly Asn 20 25 30

6

Ile Thr Arg Val Glu Ser Glu Asn
35 40

<210> 24

<211> 40

<212> PRT

<213> Hepatitis C virus

<400> 24

Leu Ser Leu Lys Ala Ala Cys Thr Gly Arg His Asp Ser Pro Asp Ala 1 5 10 15

Asp Leu Ile Glu Ala Asn Leu Leu Trp Arg Gln Glu Met Gly Gly Asn 20 25 30

Ile Thr Arg Val Glu Ser Glu Asn
35 40

<210> 25

<211> 40

<212> PRT

<213> Hepatitis C virus

<400> 25

Leu Ser Leu Lys Ala Ala Cys Thr Gly Arg His Asp Ser Pro Asp Val
1 5 10 15

Asp Leu Ile Glu Ala Asn Leu Leu Trp Arg Gln Glu Met Gly Gly Asn 20 25 30

Ile Thr Arg Val Glu Ser Glu Asn
35 40

Cons